ANTIBODIES

Contributor Information
- Name Carl Blobel
- Institute Hospital for Special Surgery
Tool Details
- Tool name: Anti-ADAM17 [17MOCYT]
- Clone: 17MOCYT
- Tool type: Antibodies
- Tool sub-type: Primary antibody
- Class: Polyclonal
- Conjugate: Unconjugated
- Reactivity: Mouse
- Host: Rabbit
- Molecular weight of the target: ~100 kDa (mature form), ~120 kDa (pro-form)
- Application: WB
- Description: ADAM17 (TACE/CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis.
- Immunogen: GST-cyto corresponding to the cytoplasmic domain of murine ADAM17
- Research area: Cancer; Cell signaling and signal transduction; Metabolism; Neurobiology; Stem cell biology
- For Research Use Only
Target Details
- Target: ADAM17
- Target molecular weight: ~100 kDa (mature form), ~120 kDa (pro-form)
- Target background: ADAM17 (TACE/CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis.
Application Details
- Application: WB
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Storage buffer: Whole serum
- Storage conditions: -20ðC
- Shipping conditions: Shipping at 4ðC
Related Tools
References
- • Horiuchi et al. 2007. J Immunol. 179(5):2686-9. PMID: 17709479.
- • Le Gall et al. 2010. J Cell Sci. 123(Pt 22):3913-22. PMID: 20980382.
- • Maretzky et al. 2011. Nat Commun. 2:229. PMID: 21407195.
- • Schl
ndorff et al. 2000. Biochem J. 347 Pt 1:131-8. PMID: 10727411. - • Zheng et al. 2002. J Biol Chem. 277(45):42463-70. PMID: 12207026.